The present study was conducted to evaluate the mechanism by which n-3 PUFA regulates the inhibitor of kBa (IkBa)/NF-kB/muscle RING finger 1 (MuRF1) pathway in C2C12 myotubes.
NF-kB is one of the most important signalling pathways linked to the loss of skeletal muscle mass in normal physiological and pathophysiological conditions (1) . NF-kB is constitutively expressed and exists in the cytosol as part of a heterotrimeric complex (2) . This complex typically comprises the DNA-binding proteins p50 and p65 and the inhibitory protein inhibitor of kBa (IkBa). Activation of NF-kB requires phosphorylation of IkBa, followed by ubiquitin conjugation and proteolysis of IkBa by the 26S proteasome (3, 4) . The activated NF-kB dimer is then translocated to the cell nucleus, where it regulates the expression of specific genes, such as the gene muscle RING finger 1 (MuRF1) (5) . MuRF1 is found in the nuclei of muscle cells and has been demonstrated to have ubiquitin-ligase activity, which depends on the presence of the RING domain for activity (6, 7) . There is growing evidence suggesting that long-chain EPA (C20 : 5n-3) can inhibit NF-kB activation by preventing the degradation of IkBa, further decreasing MuRF1 gene expression in skeletal muscle (8, 9) . However, the molecular mechanisms affected by n-3 PUFA, which leads to the inhibition of NF-kB activation, remain unclear.
Remarkably, activation of the transcription factor PPARg in the skeletal muscle can inhibit NF-kB activity (10, 11) . Previous studies have demonstrated that under normal physiological conditions, the dietary consumption of n-3 PUFA might activate PPARg in the skeletal muscle of growing-finishing pigs (12, 13) . Aas et al. (14) also found that incubation of human skeletal muscle cells with 600 mM-EPA for 24 h increased PPARg expression. Therefore, we hypothesised that under normal physiological conditions, n-3 PUFA might activate PPARg, which may in turn inhibit the IkBa/NF-kB/MuRF1 signalling pathway in the skeletal muscle.
In the present study, C2C12 myotubes were treated with either a-linolenic acid (ALA; C18 : 3n-3) or EPA (C20 : 5n-3) for 24 h. Meanwhile, knockdown of PPARg in C2C12 myotubes was achieved by RNA interference (RNAi). C2C12 myotubes with PPARg knockdown were also treated with either ALA or EPA for 24 h. The actions of ALA or EPA were compared with those of a fatty acid-free control (containing bovine serum albumin (BSA)). The aim of the present study was to investigate the mechanism by which n-3 PUFA regulates the IkBa/NF-kB/MuRF1 pathway in C2C12 myotubes.
Materials and methods

Materials
Cell culture media and supplements were obtained from Invitrogen (Carlsbad, CA, USA). Reagents for complementary DNA synthesis and the LightCycler w system were obtained from Roche Applied Science (Mannheim, Germany). ALA (C18 : 3n-3), EPA (C20 : 5n-3), essentially fatty acid-free BSA, monoclonal anti-phospho-IkBa (Ser32) antibody and anti-IkBa antibody were obtained from Cell Signaling Technology, Inc. (Beverly, MA, USA). Antibodies against NF-kB p65 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Finally, [g-32 P]ATP was obtained from Hartmann (Braunschweig, Germany).
Cell culture
Mouse C2C12 myoblasts (American Type Culture Collection, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium supplemented with 10 % fetal bovine serum, penicillin (50 units/ml) and streptomycin (50 mg/ml). When cells reached confluence, the medium was transferred to the differentiation medium containing Dulbecco's modified Eagle's medium and 2 % horse serum, which was changed every other day. After four additional days, the differentiated C2C12 cells had fused into myotubes.
Transfection of Stealthe RNA interference for PPARg knockdown in C2C12 myotubes
Transfection of Stealthe RNAi for PPARg knockdown in C2C12 myotubes was performed according to Kim et al. (15) . The PPARg Stealthe Select RNAi oligonucleotide (target accession numbers NM138712.1, M015869.2, NM138711.1 and NM005037.3) was synthesised by Invitrogen (Carlsbad, CA, USA). The Stealthe RNAi negative control duplex (Invitrogen Corporation, Carlsbad, CA, USA) was used as a control oligonucleotide. Transfection efficiency was monitored using a fluorescent oligonucleotide (BLOCK-iT fluorescent oligonucleotide; Invitrogen, Carlsbad, CA, USA) and was estimated to be 40 % in C2C12 cells. The Stealthe RNAi molecules were then transfected into C2C12 myotubes using LipofectAMINE 2000 following Invitrogen's protocols. A final concentration of 50 nM of the PPARg Stealthe Select RNAi oligonucleotide was selected for C2C12 myotubes, and the Stealthe RNAi oligonucleotides were transfected into the cells 48 h before treatment with fatty acids. The ability of the Stealthe RNAi oligonucleotide to knock down PPARg expression was analysed by Western blot and real-time quantitative PCR on whole-cell extracts.
NEFA treatment
Lipid-containing media were prepared by the conjugation of 150, 300 or 600 mM-NEFA (ALA or EPA) with NEFA-free BSA by a method modified from that described by Chavez et al. (16) . Briefly, NEFA were dissolved in ethanol and diluted 1:100 in Dulbecco's modified Eagle's medium containing 300 mM-fatty acid-free BSA. Myotubes were then incubated for 24 h in serum-free Dulbecco's modified Eagle's medium containing 300 mM-BSA either in the presence (NEFA-treated cells) or in the absence (control cells) of NEFA. After the incubation, RNA was extracted from the myotubes as described in the following section.
RNA isolation
Total RNA was extracted using the TRIzol reagent (Invitrogen Corporation, Carlsbad, CA, USA) according to the manufacturer's specifications. The RNA samples were quantified spectrophotometrically at 260 and 280 nm. The ratio of light absorbance at 260 nm to that at 280 nm was between 1·8 and 2·0, indicating that they were pure and clean. The quality of RNA was also checked by 1·0 % agarose gel electrophoresis and staining with ethidium bromide (1 mg/ml).
Reverse transcription-PCR and real-time quantitative PCR analysis
Reverse transcription (20 ml) of total RNA (1 mg) was performed using an avian myeloblastosis virus RT with a first-strand complementary DNA synthesis kit for reverse transcription-PCR. Aliquots (2 ml) of the reverse transcription reactions were then submitted in duplicate to online quantitative PCR with the LightCycler w 480 Real-Time PCR system (Roche Applied Science) with SYBR green using the FastStart DNA-Master SYBR Green I kit (Roche Applied Science). Initial real-time amplifications were examined by agarose gel electrophoresis followed by ethidium bromide staining to verify that the primer pairs amplified a single product of the predicted size. Subsequent aliquots of the PCR were checked by melting curve analysis as provided by the LightCycler w 480 Real-Time PCR System (Roche Applied Science). Primer sequences and optimal PCR annealing temperatures (t a ) are listed in Table 1 . Specific primers were synthesised commercially (Shanghai Sangon Biological Engineering Technology and Services Company, Limited, Shanghai, China). The PCR were performed in a volume of 20 ml containing 2 ml of FastStart DNA-Master SYBR Green I kit, 3 mM-MgCl 2 and primers at a concentration of 1 mM each. The instrument settings were denaturing at 958C for 10 min, forty-five cycles of denaturing at 958C for 30 s, annealing at 598C for 30 s and elongating at 728C for 8 min for PPARg, MuRF1 and b-actin. Quantification was performed by online monitoring for identification of the exact time point at which the logarithmic linear phase was distinguishable from the background. Serially diluted samples obtained by PCR with the above-mentioned primers from human myotubes were used as external standards in each run. The cycle numbers for the logarithmic linear phase were plotted against the logarithm of the concentration of the template DNA, and the concentration of complementary DNA in the different samples was calculated with the LightCycler 5.32 software package (LC-Run version 5.32; Roche Applied Science).
Isolation of nuclear extracts
Nuclear extracts were isolated according to Andrews et al. (17) . Cells were scraped into 1·5 ml of cold PBS, pelleted for 10 s and then resuspended in 400 ml of cold buffer A (10 mM-HEPES-KOH, pH 7·9 at 48C, 1·5 mMMgCl 2 , 10mM-KCl, 0·5 mM-dithiothreitol, 0·2 mM-phenylmethylsulphonyl fluoride, 5 mg/ml aprotinin and 2 mg/ml leupeptin) by flicking the tube. Cells were allowed to swell on ice for 10 min and were then vortexed for 10 s. Samples were then centrifuged for 10 s, and the supernatant fraction was discarded. Pellets were resuspended in 50 ml of cold buffer C (20 mM-HEPES -KOH, pH 7·9 at 48C, 25 % glycerol, 420 mM-NaCl, 1·5 mM-MgCl 2 , 0·2 mM-EDTA, 0·5 mM-dithiothreitol, 0·2 mM-phenylmethylsulphonyl fluoride, 5 mg/ml aprotinin and 2 mg/ml leupeptin) and incubated on ice for 20 min for high-salt extraction. Cellular debris was removed by centrifugation for 2 min at 48C, and the supernatant fraction (containing DNAbinding proteins) was stored at 2 808C. The nuclear extract concentration was determined by the Bradford method.
Electrophoretic mobility shift assay
The transcription factor consensus oligonucleotides for the NF-kB-responsive element (5 0 -AGT TGA GGG GAC TTT CCC AGG C-3 0 ) and the activator protein-1-responsive element (5 0 -CGC TTG ATG AGT CAG CCG GAA-3 0 ) were purchased from Santa Cruz Biotechnology, Inc. The probes were labelled with [g-32 P]-ATP using T4 polynucleotide kinase (Boehringer-Mannheim, Lewes, UK) and purified on Sephadex G-25 spin chromatography columns (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK). For the binding reactions, the nuclear extract (1 mg of protein) was incubated in a 20 ml volume containing electrophoretic mobility shift assay-binding buffer (20 mM-HEPES, pH 7·5, 50 mM-NaCl, 1 mM-EDTA, 1 mM-dithiothreitol, 0·05 % NP-40 and 10 % glycerol), 0·25 ng [g-32 P]-labelled probe, BSA (1 mg/ml; Cell Signaling Technology, Inc.) and poly d(I-C) (100 ng/ml) for 20 min at room temperature. The specificity of the binding reaction was determined by co-incubating duplicate samples with either a 100-fold molar excess of an unlabelled oligonucleotide probe or an anti-NF-kB antibody (anti-p65; Santa Cruz Biotechnology, Inc.). Protein-nucleic acid complexes were resolved using a non-denaturing polyacrylamide gel consisting of 6 % acrylamide run in 5 mM-Tris (pH 8·3) and 38 mM-glycine for 2 h at 200 V. Gels were then transferred to Whatman 3M paper (Whatman, Inc., Clifton, NJ, USA), dried under a vacuum at 808C for 1 h and exposed to a photographic film at 2 708C with an intensifying screen.
Immunoblotting
To obtain total proteins, C2C12 myotubes were homogenised in cold lysis buffer (5 mM-Tris -HCl, pH 7·4, 1 mM-EDTA, 0·1 mM-phenylmethylsulphonyl fluoride, 1 mM-sodium orthovanadate and 5·4 mg/ml aprotinin). The homogenate was then centrifuged at 10 000 g for 30 min at 48C. For obtaining total membranes from C2C12 myotubes, cells were collected into 10 ml of ice-cold HES buffer (250 mM-sucrose, 1 M-EDTA, 1 M-phenylmethylsulphonyl fluoride, 1 mM-pepstatin, 1 mM-aprotinin, 1 mM-leupeptin and 20 M-HEPES, pH 7·4) and subsequently homogenised at 48C. After centrifugation at 1000 g for 3 min at 48C to remove large cell debris and unbroken cells, the supernatant was centrifuged at 245 000 g for 90 min at 48C to yield a pellet of total cellular membranes. Proteins (30 mg) were separated by SDS-PAGE on 10 % separation gels and transferred to Immobilon polyvinylidene diflouride membranes (Millipore, Bedford, MA, USA). Western blot analysis was performed using antibodies against phospho-IkBa (Ser32), total IkBa and PPARg (Santa Cruz Biotechnology, Inc.). Detection was achieved using the EZ-ECL chemiluminescence detection kit (Biological Industries, Beit Haemek Limited, Beit Haemek, Israel). The equal loading of proteins was assessed by red phenol staining. The size of the detected proteins was estimated using protein molecular mass standards (Invitrogen, Barcelona, Spain).
Statistical analysis
Data are presented as means with their standard errors. Differences between group means were determined by a one-way ANOVA using the computer program GraphPad Instat (version 2.03; GraphPad Software, Inc., San Diego, CA, USA). When significant variations were found, the Tukey-Kramer multiple comparison test was performed. Differences were considered significant at P, 0·05.
Results
Effect of 24 h treatment with 150, 300 or 600 mM-n-3 PUFA on the levels of phosphorylated inhibitor of kBa and total inhibitor of kBa in C2C12 myotubes
In the present study, two long-chain n-3 PUFA were chosen: ALA (a C18 : 3n-3 PUFA) and EPA (a C20 : 5n-3 PUFA). In addition, BSA was used as the fatty acid-free control. After treatment with 150, 300 or 600 mM-ALA and -EPA for 24 h, the levels of phosphorylated IkBa (p-IkBa) and total IkBa in C2C12 myotubes were measured by Western blot. Compared with the BSA control, a 24 h incubation of C2C12 myotubes with 150 mM (Fig. 1(a) ) and 300 mM ( Fig. 1(b) ) ALA and EPA, respectively, did not affect the levels of p-IkBa and total IkBa. The effect of 600 mM-ALA and -EPA on the IkBa protein levels in C2C12 myotubes is presented in Fig. 1(c) . As expected, EPA (600 mM, 24 h) decreased IkBa phosphorylation and caused an approximately 86 % increase in total IkBa protein levels (P, 0·01). However, 600 mM-ALA did not affect the levels of p-IkBa or total IkBa (P. 0·05). Taken together, these data suggested that 600 mM-EPA, but not ALA, prevented the degradation of IkBa by decreasing the phosphorylation of IkBa, increasing the total IkBa protein levels in C2C12 myotubes.
Effect of 24 h treatment with 600 mM-n-3 PUFA on the NF-kB-binding activity in C2C12 myotubes
To test whether incubation of C2C12 cells with 600 mM-ALA or -EPA for 24 h led to an effect on NF-kB activity, we performed electrophoretic mobility shift assay studies (Fig. 2) . 
NF-κB
NF-κB probe ALA EPA BSA Cold Fig. 2 . NF-kB DNA-binding activity via the electrophoretic mobility shift assay (EMSA). C2C12 myotubes were incubated with 600 mM-a-linolenic acid (ALA) or 600 mM-EPA for 24 h. Bovine serum albumin (BSA) was used as the fatty acid-free control. Total nuclear protein was subsequently isolated and analysed by the EMSA for NF-kB DNA-binding activity using a 32 P-labelled double-stranded oligonucleotide for the NF-kB. An additional non-labelled probe was added into the competition assay (cold). Data are representative of three independent experiments.
Compared with BSA, incubation of C2C12 myotubes with 600 mM-EPA for 24 h decreased the NF-kB DNA-binding activity in C2C12 myotubes (P, 0·01). Similar to the effect on the IkBa protein levels, 600 mM-ALA had no effect after 24 h on the NF-kB DNA-binding activity in C2C12 myotubes (P. 0·05).
Effect of 24 h treatment with 600 mM-n-3 PUFA on the gene expression of muscle RING finger 1 and PPARg in C2C12 myotubes
Because NF-kB is translocated to the cell nucleus upon activation, leading to the stimulation of MuRF1 gene expression (5) , we next investigated whether incubation of C2C12 cells with 600 mM-ALA or -EPA for 24 h affected MuRF1 mRNA expression (Fig. 3(b) ). C2C12 myotubes incubated in the presence of 600 mM-EPA for 24 h caused a 3·38-fold reduction in the levels of MuRF1 mRNA (P, 0·01). However, compared with BSA, 600 mM-ALA did not affect MuRF1 mRNA expression (P. 0·05).
PPARg gene expression data are presented in Fig. 3(a) . Incubation of C2C12 myotubes in the presence of 600 mM-EPA for 24 h resulted in a 2·3-fold induction of PPARg expression (P, 0·01), whereas 24 h incubation with 600 mM-ALA had no effect (P. 0·05).
Effect of 24 h treatment with 600 mM-n-3 PUFA on the inhibitor of kBa/NF-kB/muscle RING finger 1 pathway in C2C12 myotubes with PPARg knockdown To confirm that the inhibition of the IkBa/NF-kB/MuRF1 pathway by n-3 PUFA is mediated via activation of PPARg mRNA expression, we examined the effect of n-3 PUFA on the IkBa/NF-kB/MuRF1 pathway in C2C12 myotubes with PPARg knockdown. As such, the C2C12 myotubes transfected with either the negative control Stealthe RNAi oligonucleotide or the PPARg Stealthe RNAi oligonucleotide were incubated for 48 h. Transfection of Stealthe RNAi for PPARg knockdown in C2C12 myotubes was found to significantly decrease PPARg protein expression (Fig. 4(a) and (b) ) and PPARg mRNA expression (Fig. 4(c) ) to approximately 50 and 60 % of their normal levels (P, 0·01), respectively. Negative control Stealthe RNAi treatment had no influence on PPARg mRNA and protein expression (P. 0·05).
Compared with the Stealthe RNAi-transfected control, 600 mM-EPA, but not ALA, prevented the degradation of IkBa by decreasing the phosphorylation of IkBa (P,0·01), thus increasing the total IkBa protein levels ( Fig. 5(a) ) in C2C12 myotubes transfected with the negative control Stealthe RNAi oligonucleotide (P,0·01). It was further observed that 600 mM-EPA decreased NF-kB DNA-binding activity (Fig. 5(b) ) and inhibited MuRF1 mRNA expression (Fig. 6 ) in C2C12 myotubes transfected with the negative control Stealthe RNAi oligonucleotide (P,0·01). However, in C2C12 myotubes transfected with the PPARg Stealthe RNAi oligonucleotide, treatment with 600 mM-ALA or -EPA for 24 h did not affect the levels of p-IkBa or total IkBa (Fig. 5(a) ), NF-kB DNA-binding activity (Fig. 5(b) ) or MuRF1 mRNA expression (Fig. 6 ) compared with the PPARg Stealthe RNAi-transfected control (P.0·05).
Discussion
The key to NF-kB regulation is the IkBa protein, which is retained in the cytoplasm. Phosphorylation of IkBa by IkB kinases triggers its polyubiquitinylation and degradation, thereby releasing NF-kB, which can then translocate to the nucleus. In the present study, C2C12 myotubes incubated in the presence of 150, 300 or 600 mM-ALA for 24 h did not have different levels of p-IkBa or total IkBa compared with the fatty acid-free BSA control, suggesting that ALA was not able to regulate NF-kB activity by preventing phosphorylation of IkBa and decreasing total IkBa degradation in C2C12 myotubes. Interestingly, the addition of 600 mM-EPA (C20 : 5n-3) to the cells decreased IkBa phosphorylation and caused an approximate 86 % increase in total IkBa protein levels. It was further observed that 600 mM-EPA inhibited NF-kB activation in C2C12 myotubes. These results are in general agreement with other studies showing that EPA inhibited NF-kB activation by preventing IkBa phosphorylation, thus BSA ALA EPA Fig. 3 . Effects of n-3 PUFA on the PPARg and muscle RING finger 1 (MuRF1) gene expression. C2C12 myotubes were incubated with 600 mMa-linolenic acid (ALA, B) or 600 mM-EPA ( ) for 24 h. Bovine serum albumin (BSA, A) was used as the fatty acid-free control. The PPARg mRNA and MuRF1 mRNA levels were determined using real-time PCR analysis, and the relative abundance of mRNA was calculated after normalisation to b-actin. PPARg (a) and MuRF1 (b). Data are expressed as the mean values and standard deviations of three different experiments. ** Mean values were significantly different from that of the control group (P, 0·01).
further reducing the degradation of the inhibitory IkBa protein (18, 19) . In the present study, there was no effect on the levels of p-IkBa or total IkBa following a chronic exposure to 150 or 300 mM-EPA, suggesting that the effect of EPA on the levels of p-IkBa and total IkBa may be dependent on the concentration of the fatty acid. Remarkably, Lo et al. (20) reported that proteolysis-inducing factor, isolated from a cachexia-inducing murine tumour, activated NF-kB by inducing the degradation of IkBa in C2C12 myotubes, and that 50 mM-EPA effectively attenuated the proteolysis-inducing factor-induced IkBa/NF-kB pathway under various pathophysiological conditions. Therefore, the present study provides evidence that the effect of EPA on the IkBa/NF-kB pathway requires higher concentrations of fatty acids under normal physiological conditions than under pathophysiological conditions. MuRF1 is a 40 kDa protein that contains a RING domain at its amino-terminal end as well as two coiled-coil domains in its central region, and is found in the nuclei of muscle cells (21, 22) . MuRF1 has been demonstrated to have ubiquitin-ligase activity that requires the presence of the RING domain for normal activity (6) . Previous studies revealed that the NF-kB was translocated to the cell nucleus upon activation and led to the stimulation of MuRF1 gene expression (5) . In the present study, incubation of C2C12 myotubes in the presence of 600 mM-EPA for 24 h caused a 3·38-fold induction in the level of MuRF1 mRNA, whereas a 24 h incubation period with 600 mM-ALA did not affect MuRF1 mRNA expression. These results revealed that EPA, but not ALA, inhibited NF-kB activation by preventing the degradation of IkBa and further decreasing the MuRF1 gene expression in C2C12 myotubes. 6 . The effect of n-3 PUFA on the muscle RING finger 1 (MuRF1) gene expression in C2C12 myotubes transfected with the PPARg Stealthe RNA interference (RNAi) oligonucleotide. After the transfection of C2C12 myotubes with either the negative control Stealthe RNAi oligonucleotide or the PPARg Stealthe RNAi oligonucleotide for 48 h, C2C12 myotubes were incubated with 600 mM-a-linolenic acid (ALA, B) or 600 mM-EPA ( ) for 24 h. Bovine serum albumin (BSA, A) was used as the fatty acid-free control. MuRF1 mRNA was determined using real-time PCR analysis, and the relative abundance of mRNA was calculated after normalisation to b-actin. Data are expressed as the mean values and standard deviations of three independent experiments. ** Mean values were significantly different from that of the negative Stealthe RNAi-transfected control group (P, 0·01).
We next investigated the effect of incubation of C2C12 myotubes with 600 mM-ALA or -EPA for 24 h on PPARg gene expression. PPARg is a member of the nuclear receptor superfamily of PPAR, and its main function was originally thought to regulate adipocyte differentiation (23, 24) . Recently, growing evidence points to its implication in the regulation of the immune response, particularly in inflammation control (25) . The strongest PPARg expression has been observed in adipose tissues and in the spleen, with a lower expression in the kidney, large intestine, heart, lung, small intestine and skeletal muscle (26) . In the present study, it was observed that C2C12 myotubes incubated in the presence of EPA (600 mM, 24 h) resulted in a 1·47-fold induction of PPARg expression compared with the BSA control, which is in line with a previous report by Aas et al. (14) , who found a 2·3-fold increase in PPARg expression after exposure of human skeletal muscle cells to EPA (600 mM, 24 h). It is noteworthy that C2C12 myotubes incubated in the presence of ALA (600 mM, 24 h) had no change in PPARg mRNA levels. Chambrier et al. (27) also found that EPA (50 mM, 6h) induced PPARg mRNA levels in human adipocytes, but that ALA (50 mM, 6 h), a precursor of EPA, did not change PPARg mRNA levels. Furthermore, they observed that it was likely that the metabolism of ALA was not efficient enough to lead to an effective concentration of EPA in human adipocytes (27) . Taken together, these results demonstrated that long-chain EPA could induce PPARg mRNA expression in skeletal muscle cells, while ALA, with a shorter chain length, was not able to affect PPARg mRNA expression.
Additionally, the present results revealed that EPA, but not ALA, was effective at inhibiting the IkBa/NF-kB/MuRF1 pathway in C2C12 myotubes. However, the reason why ALA could not regulate the IkBa/NF-kB/MuRF1 pathway in C2C12 myotubes is poorly documented. Interestingly, we discovered that EPA could induce PPARg mRNA expression in skeletal muscle cells, while ALA was not able to affect PPARg mRNA expression. Therefore, the reason why ALA could not regulate the IkBa/NF-kB/MuRF1 pathway may have been that ALA was not able to affect PPARg mRNA expression in C2C12 myotubes.
To investigate whether EPA inhibited the IkBa/NF-kB/ MuRF1 pathway via activation of PPARg mRNA expression, PPARg knockdown by RNAi was used to decrease PPARg mRNA and protein expression to approximately 50 and 60 %, respectively, of their normal levels in C2C12 myotubes. Interestingly, it was observed that treatment with 600 mM-EPA for 24 h did not affect the levels of p-IkBa, total IkBa, NF-kB DNA-binding activity or MuRF1 mRNA expression in C2C12 myotubes with PPARg knockdown. These results demonstrated that PPARg knockdown by RNAi abolished the suppressive effects of EPA on the IkBa/NF-kB/MuRF1 pathway in C2C12 myotubes, supporting the claim that the effects of EPA are mediated via PPARg activation. Taken together, these results revealed that EPA, but not ALA, activated PPARg, which may in turn have inhibited the IkBa/NF-kB/MuRF1 signalling pathway in C2C12 myotubes.
